CoChat
Sign Up
Cited by 152Antioxidant Activity and Oxidative StressNitric Oxide and Endothelin EffectsAtherosclerosis and Cardiovascular Diseases

Lipoxidation in cardiovascular diseases

Open access
Gianazza, Erica, Brioschi, Maura, Fernandez, Alma Martinez, Banfi, Cristina·2019·Redox Biology
DOI 10.1016/j.redox.2019.101119PMC PMC6859589
Open this paper in CoChat — free account

Abstract

Lipids can go through lipid peroxidation, an endogenous chain reaction that consists in the oxidative degradation of lipids leading to the generation of a wide variety of highly reactive carbonyl species (RCS), such as short-chain carbonyl derivatives and oxidized truncated phospholipids. RCS exert a wide range of biological effects due to their ability to interact and covalently bind to nucleophilic groups on other macromolecules, such as nucleic acids, phospholipids, and proteins, forming reversible and/or irreversible modifications and generating the so-called advanced lipoxidation end-products (ALEs). Lipoxidation plays a relevant role in the onset of cardiovascular diseases (CVD), mainly in the atherosclerosis-based diseases in which oxidized lipids and their adducts have been extensively characterized and associated with several processes responsible for the onset and development of atherosclerosis, such as endothelial dysfunction and inflammation. Herein we will review the current knowledge on the sources of lipids that undergo oxidation in the context of cardiovascular diseases, both from the bloodstream and tissues, and the methods for detection, characterization, and quantitation of their oxidative products and protein adducts. Moreover, lipoxidation and ALEs have been associated with many oxidative-based diseases, including CVD, not only as potential biomarkers but also as therapeutic targets. Indeed, several therapeutic strategies, acting at different levels of the ALEs cascade, have been proposed, essentially blocking ALEs formation, but also their catabolism or the resulting biological responses they induce. However, a deeper understanding of the mechanisms of formation and targets of ALEs could expand the available therapeutic strategies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.redox.2019.101119

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 313

  1. [1]Shibata T. Shimizu K. Hirano K. Adductome-based identification of biomarkers for lipid peroxidation J. Biol. Chem. 292 2017 8223 8235 28341743 PMC5437230
  2. [2]Ayala A. Munoz M.F. Arguelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal Oxid. Med. Cell Longev. 2014 2014 360438 PMC4066722 24999379
  3. [3]Lee S.H. Blair I.A. Characterization of 4-oxo-2-nonenal as a novel product of lipid peroxidation Chem. Res. Toxicol. 13 2000 698 702 10956056
  4. [4]Massey K.A. Nicolaou A. Lipidomics of oxidized polyunsaturated fatty acids Free Radic. Biol. Med. 59 2013 45 55 22940496 PMC3991857
  5. [6]Miller E. Morel A. Saso L. Isoprostanes and neuroprostanes as biomarkers of oxidative stress in neurodegenerative diseases Oxid. Med. Cell Longev. 2014 2014 572491 PMC4020162 24868314
  6. [7]Pamplona R. Advanced lipoxidation end-products Chem. Biol. Interact. 192 2011 14 20 21238437
  7. [8]Wei X. Yin H. Covalent modification of DNA by alpha, beta-unsaturated aldehydes derived from lipid peroxidation: recent progress and challenges Free Radic. Res. 49 2015 905 917 25968945
  8. [9]Naudi A. Jove M. Ayala V. Non-enzymatic modification of aminophospholipids by carbonyl-amine reactions Int. J. Mol. Sci. 14 2013 3285 3313 23385235 PMC3588044
  9. [10]Domingues R.M. Domingues P. Melo T. Lipoxidation adducts with peptides and proteins: deleterious modifications or signaling mechanisms? J. Proteom. 92 2013 110 131 23770299
  10. [11]Lee S. Birukov K.G. Romanoski C.E. Role of phospholipid oxidation products in atherosclerosis Circ. Res. 111 2012 778 799 22935534 PMC3563283
  11. [12]Fu M.X. Requena J.R. Jenkins A.J. The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions J. Biol. Chem. 271 1996 9982 9986 8626637
  12. [13]Castro J.P. Jung T. Grune T. 4-Hydroxynonenal (HNE) modified proteins in metabolic diseases Free Radic. Biol. Med. 111 2017 309 315 27815191
  13. [15]Schaur R.J. Basic aspects of the biochemical reactivity of 4-hydroxynonenal Mol. Aspect. Med. 24 2003 149 159 12892992
  14. [16]Zhang W.H. Liu J. Xu G. Model studies on protein side chain modification by 4-oxo-2-nonenal Chem. Res. Toxicol. 16 2003 512 523 12703968
  15. [17]Maeshima T. Honda K. Chikazawa M. Quantitative analysis of acrolein-specific adducts generated during lipid peroxidation-modification of proteins in vitro: identification of N(tau)-(3-propanal)histidine as the major adduct Chem. Res. Toxicol. 25 2012 1384 1392 22716039
  16. [18]Del Rio D. Stewart A.J. Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress Nutr. Metabol. Cardiovasc. Dis. 15 2005 316 328 16054557
  17. [19]Roberts L.J. 2nd Milne G.L. Isoprostanes J. Lipid Res. 50 Suppl 2009 S219 S223 18957694 PMC2674741
  18. [20]Morrow J.D. Hill K.E. Burk R.F. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism Proc. Natl. Acad. Sci. U. S. A. 87 1990 9383 9387 2123555 PMC55169
  19. [21]Mallat Z. Philip I. Lebret M. Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure Circulation 97 1998 1536 1539 9593557
  20. [22]Yen H.C. Chen T.W. Yang T.C. Levels of F2-isoprostanes, F4-neuroprostanes, and total nitrate/nitrite in plasma and cerebrospinal fluid of patients with traumatic brain injury Free Radic. Res. 49 2015 1419 1430 26271312
  21. [23]Bartova R. Petrlenicova D. Oresanska K. Changes in levels of oxidative stress markers and some neuronal enzyme activities in cerebrospinal fluid of multiple sclerosis patients Neuroendocrinol. Lett. 37 2016 102 106 27179571
  22. [24]Chen Y. Morrow J.D. Roberts L.J. 2nd Formation of reactive cyclopentenone compounds in vivo as products of the isoprostane pathway J. Biol. Chem. 274 1999 10863 10868 10196163
  23. [25]Milne G.L. Zanoni G. Porta A. The cyclopentenone product of lipid peroxidation, 15-A2t-isoprostane, is efficiently metabolized by HepG2 cells via conjugation with glutathione Chem. Res. Toxicol. 17 2004 17 25 14727915
  24. [26]Galano J.M. Lee J.C. Gladine C. Non-enzymatic cyclic oxygenated metabolites of adrenic, docosahexaenoic, eicosapentaenoic and alpha-linolenic acids; bioactivities and potential use as biomarkers Biochim. Biophys. Acta 1851 2015 446 455 25463478
  25. [27]VanRollins M. Woltjer R.L. Yin H. F2-dihomo-isoprostanes arise from free radical attack on adrenic acid J. Lipid Res. 49 2008 995 1005 18250368 PMC2311438
  26. [28]Salomon R.G. Batyreva E. Kaur K. Isolevuglandin-protein adducts in humans: products of free radical-induced lipid oxidation through the isoprostane pathway Biochim. Biophys. Acta 1485 2000 225 235 10832102
  27. [29]Yin H. Porter N.A. New insights regarding the autoxidation of polyunsaturated fatty acids Antioxidants Redox Signal. 7 2005 170 184 15650406
  28. [30]Fessel J.P. Jackson Roberts L. Isofurans: novel products of lipid peroxidation that define the occurrence of oxidant injury in settings of elevated oxygen tension Antioxidants Redox Signal. 7 2005 202 209 15650408
  29. [31]Fruhwirth G.O. Loidl A. Hermetter A. Oxidized phospholipids: from molecular properties to disease Biochim. Biophys. Acta 1772 2007 718 736 17570293
  30. [32]Parthasarathy S. Steinberg D. Witztum J.L. The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis Annu. Rev. Med. 43 1992 219 225 1580586
  31. [33]Khazaei M. Moien-Afshari F. Laher I. Vascular endothelial function in health and diseases Pathophysiology 15 2008 49 67 18434105
  32. [34]Sandoo A. van Zanten J.J. Metsios G.S. The endothelium and its role in regulating vascular tone Open Cardiovasc. Med. J. 4 2010 302 312 21339899 PMC3040999
  33. [35]Park K.H. Park W.J. Endothelial dysfunction: clinical implications in cardiovascular disease and therapeutic approaches J. Kor. Med. Sci. 30 2015 1213 1225 PMC4553666 26339159
  34. [36]Bonetti P.O. Lerman L.O. Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk Arterioscler. Thromb. Vasc. Biol. 23 2003 168 175 12588755
  35. [37]Xu S. Ogura S. Chen J. LOX-1 in atherosclerosis: biological functions and pharmacological modifiers Cell. Mol. Life Sci. 70 2013 2859 2872 23124189 PMC4142049
  36. [38]Yoshimoto R. Fujita Y. Kakino A. The discovery of LOX-1, its ligands and clinical significance Cardiovasc. Drugs Ther. 25 2011 379 391 21805404 PMC3204104
  37. [39]Murphy A.J. Woollard K.J. High-density lipoprotein: a potent inhibitor of inflammation Clin. Exp. Pharmacol. Physiol. 37 2010 710 718 19930423
  38. [41]Martin-Ventura J.L. Rodrigues-Diez R. Martinez-Lopez D. Oxidative stress in human atherothrombosis: sources, markers and therapeutic targets Int. J. Mol. Sci. 18 2017 pii: E2315 PMC5713284 29099757
  39. [42]Malle E. Marsche G. Arnhold J. Modification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid Biochim. Biophys. Acta 1761 2006 392 415 16698314
  40. [43]Fogelman A.M. Shechter I. Seager J. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages Proc. Natl. Acad. Sci. U. S. A. 77 1980 2214 2218 6769124 PMC348683
  41. [44]Yassine H.N. Jackson A.M. Reaven P.D. The application of multiple reaction monitoring to assess Apo A-I methionine oxidations in diabetes and cardiovascular disease Transl. Proteom. 4–5 2014 18 24 PMC4331021 25705587
  42. [45]Horkko S. Bird D.A. Miller E. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins J. Clin. Invest. 103 1999 117 128 9884341 PMC407862
  43. [46]Que X. Hung M.Y. Yeang C. Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice Nature 558 2018 301 306 29875409 PMC6033669
  44. [47]Forbes S.P. Druhan L.J. Guzman J.E. Mechanism of 4-HNE mediated inhibition of hDDAH-1: implications in no regulation Biochemistry 47 2008 1819 1826 18171027
  45. [48]Okada T. Morino K. Nakagawa F. N-3 polyunsaturated fatty acids decrease the protein expression of soluble epoxide hydrolase via oxidative stress-induced P38 kinase in rat endothelial cells Nutrients 9 2017 PMC5537774 28672788
  46. [49]Wang Y.X. Ulu A. Zhang L.N. Soluble epoxide hydrolase in atherosclerosis Curr. Atheroscler. Rep. 12 2010 174 183 20425256 PMC2857794
  47. [50]Ishikado A. Morino K. Nishio Y. 4-Hydroxy hexenal derived from docosahexaenoic acid protects endothelial cells via Nrf2 activation PLoS One 8 2013 e69415 PMC3720569 23936010
  48. [51]Leonarduzzi G. Gamba P. Gargiulo S. Inflammation-related gene expression by lipid oxidation-derived products in the progression of atherosclerosis Free Radic. Biol. Med. 52 2012 19 34 22037514
  49. [52]Shanmugam N. Figarola J.L. Li Y. Proinflammatory effects of advanced lipoxidation end products in monocytes Diabetes 57 2008 879 888 18003754 PMC2695452
  50. [53]van Tits L.J. Stienstra R. van Lent P.L. Oxidized LDL enhances pro-inflammatory responses of alternatively activated M2 macrophages: a crucial role for Kruppel-like factor 2 Atherosclerosis 214 2011 345 349 21167486
  51. [54]Kim C.E. Lee S.J. Seo K.W. Acrolein increases 5-lipoxygenase expression in murine macrophages through activation of ERK pathway Toxicol. Appl. Pharmacol. 245 2010 76 82 20153347
  52. [55]O'Toole T.E. Zheng Y.T. Hellmann J. Acrolein activates matrix metalloproteinases by increasing reactive oxygen species in macrophages Toxicol. Appl. Pharmacol. 236 2009 194 201 19371603 PMC2677519
  53. [56]Moghe A. Ghare S. Lamoreau B. Molecular mechanisms of acrolein toxicity: relevance to human disease Toxicol. Sci. 143 2015 242 255 25628402 PMC4306719
  54. [57]Schrimpe-Rutledge A.C. Fong K.Y. Wright D.W. Impact of 4-hydroxynonenal on matrix metalloproteinase-9 regulation in lipopolysaccharide-stimulated RAW 264.7 cells Cell Biochem. Funct. 33 2015 59 66 25663587
  55. [58]Lee S.J. Seo K.W. Yun M.R. 4-Hydroxynonenal enhances MMP-2 production in vascular smooth muscle cells via mitochondrial ROS-mediated activation of the Akt/NF-kappaB signaling pathways Free Radic. Biol. Med. 45 2008 1487 1492 18805481
  56. [59]Akiba S. Kumazawa S. Yamaguchi H. Acceleration of matrix metalloproteinase-1 production and activation of platelet-derived growth factor receptor beta in human coronary smooth muscle cells by oxidized LDL and 4-hydroxynonenal Biochim. Biophys. Acta 1763 2006 797 804 16876267
  57. [60]Vatsyayan R. Kothari H. Pendurthi U.R. 4-Hydroxy-2-nonenal enhances tissue factor activity in human monocytic cells via p38 mitogen-activated protein kinase activation-dependent phosphatidylserine exposure Arterioscler. Thromb. Vasc. Biol. 33 2013 1601 1611 23640483 PMC3883589
  58. [61]Lee T.J. Lee J.T. Moon S.K. Age-related differential growth rate and response to 4-hydroxynonenal in mouse aortic smooth muscle cells Int. J. Mol. Med. 17 2006 29 35 16328008
  59. [62]Munzel T. Camici G.G. Maack C. Impact of oxidative stress on the heart and vasculature: part 2 of a 3-part series J. Am. Coll. Cardiol. 70 2017 212 229 28683969 PMC5663297
  60. [63]Guzik T.J. Sadowski J. Kapelak B. Systemic regulation of vascular NAD(P)H oxidase activity and nox isoform expression in human arteries and veins Arterioscler. Thromb. Vasc. Biol. 24 2004 1614 1620 15256399
  61. [65]Zarkovic K. Larroque-Cardoso P. Pucelle M. Elastin aging and lipid oxidation products in human aorta Redox Biol. 4 2015 109 117 25553420 PMC4309857
  62. [66]Subbotin V.M. Neovascularization of coronary tunica intima (DIT) is the cause of coronary atherosclerosis. Lipoproteins invade coronary intima via neovascularization from adventitial vasa vasorum, but not from the arterial lumen: a hypothesis Theor. Biol. Med. Model. 9 2012 11 22490844 PMC3492120
  63. [67]Larroque-Cardoso P. Mucher E. Grazide M.H. 4-Hydroxynonenal impairs transforming growth factor-beta1-induced elastin synthesis via epidermal growth factor receptor activation in human and murine fibroblasts Free Radic. Biol. Med. 71 2014 427 436 24561579
  64. [68]Lee S.J. Kim C.E. Yun M.R. 4-Hydroxynonenal enhances MMP-9 production in murine macrophages via 5-lipoxygenase-mediated activation of ERK and p38 MAPK Toxicol. Appl. Pharmacol. 242 2010 191 198 19837106
  65. [69]Kolwicz S.C. Jr. Purohit S. Tian R. Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes Circ. Res. 113 2013 603 616 23948585 PMC3845521
  66. [70]Lopaschuk G.D. Ussher J.R. Folmes C.D. Myocardial fatty acid metabolism in health and disease Physiol. Rev. 90 2010 207 258 20086077
  67. [71]Fillmore N. Mori J. Lopaschuk G.D. Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy Br. J. Pharmacol. 171 2014 2080 2090 24147975 PMC3976623
  68. [72]Chiu H.C. Kovacs A. Blanton R.M. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy Circ. Res. 96 2005 225 233 15618539
  69. [73]Finck B.N. Lehman J.J. Leone T.C. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus J. Clin. Invest. 109 2002 121 130 11781357 PMC150824
  70. [74]Watanabe K. Fujii H. Takahashi T. Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity J. Biol. Chem. 275 2000 22293 22299 10801788
  71. [75]Burkart E.M. Sambandam N. Han X. Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart J. Clin. Invest. 117 2007 3930 3939 18037994 PMC2082147
  72. [76]Shiraki T. Kamiya N. Shiki S. Alpha,beta-unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor gamma J. Biol. Chem. 280 2005 14145 14153 15695504
  73. [77]Itoh T. Fairall L. Amin K. Structural basis for the activation of PPARgamma by oxidized fatty acids Nat. Struct. Mol. Biol. 15 2008 924 931 19172745 PMC2939985
  74. [78]Benedusi V. Martorana F. Brambilla L. The peroxisome proliferator-activated receptor gamma (PPARgamma) controls natural protective mechanisms against lipid peroxidation in amyotrophic lateral sclerosis J. Biol. Chem. 287 2012 35899 35911 22910911 PMC3476258
  75. [79]Finck B.N. Kelly D.P. Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease Circulation 115 2007 2540 2548 17502589
  76. [80]Nguyen B.Y. Ruiz-Velasco A. Bui T. Mitochondrial function in the heart: the insight into mechanisms and therapeutic potentials Br. J. Pharmacol. 2018 PMID: 29968316 PMC6887906 29968316
  77. [81]Anderson E.J. Katunga L.A. Willis M.S. Mitochondria as a source and target of lipid peroxidation products in healthy and diseased heart Clin. Exp. Pharmacol. Physiol. 39 2012 179 193 22066679 PMC3827773
  78. [82]Chicco A.J. Sparagna G.C. Role of cardiolipin alterations in mitochondrial dysfunction and disease Am. J. Physiol. Cell Physiol. 292 2007 C33 C44 16899548
  79. [83]Luo J. Hill B.G. Gu Y. Mechanisms of acrolein-induced myocardial dysfunction: implications for environmental and endogenous aldehyde exposure Am. J. Physiol. Heart Circ. Physiol. 293 2007 H3673 H3684 17921335
  80. [84]Wu Z. He E.Y. Scott G.I. alpha,beta-Unsaturated aldehyde pollutant acrolein suppresses cardiomyocyte contractile function: role of TRPV1 and oxidative stress Environ. Toxicol. 30 2015 638 647 24376112
  81. [85]Refsgaard H.H. Tsai L. Stadtman E.R. Modifications of proteins by polyunsaturated fatty acid peroxidation products Proc. Natl. Acad. Sci. U. S. A. 97 2000 611 616 10639127 PMC15378
  82. [86]Glei M. Schaeferhenrich A. Claussen U. Comet fluorescence in situ hybridization analysis for oxidative stress-induced DNA damage in colon cancer relevant genes Toxicol. Sci. 96 2007 279 284 17192441
  83. [87]Baker A.G. Wiesler D. Novotny M.V. Tandem mass spectrometry of model peptides modified with trans-2-hexenal, a product of lipid peroxidation J. Am. Soc. Mass Spectrom. 10 1999 613 624 10384725
  84. [88]Ping P. Baines C.P. Gu Y. Cardiac toxic effects of trans-2-hexenal are mediated by induction of cardiomyocyte apoptotic pathways Cardiovasc. Toxicol. 3 2003 341 351 14734831
  85. [89]Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress Prog. Lipid Res. 42 2003 318 343 12689622
  86. [90]Chapple S.J. Cheng X. Mann G.E. Effects of 4-hydroxynonenal on vascular endothelial and smooth muscle cell redox signaling and function in health and disease Redox Biol. 1 2013 319 331 24024167 PMC3757694
  87. [91]Zhang Y. Sano M. Shinmura K. 4-hydroxy-2-nonenal protects against cardiac ischemia-reperfusion injury via the Nrf2-dependent pathway J. Mol. Cell. Cardiol. 49 2010 576 586 20685357
  88. [92]Lopez-Bernardo E. Anedda A. Sanchez-Perez P. 4-Hydroxynonenal induces Nrf2-mediated UCP3 upregulation in mouse cardiomyocytes Free Radic. Biol. Med. 88 2015 427 438 25843654
  89. [93]Nagy E. Jermendy A.L. Merkely B. Clinical importance of epicardial adipose tissue Arch. Med. Sci. 13 2017 864 874 28721155 PMC5507110
  90. [94]Li R. Wang W.Q. Zhang H. Adiponectin improves endothelial function in hyperlipidemic rats by reducing oxidative/nitrative stress and differential regulation of eNOS/iNOS activity Am. J. Physiol. Endocrinol. Metab. 293 2007 E1703 E1708 17895290
  91. [95]Sacks H.S. Fain J.N. Human epicardial adipose tissue: a review Am. Heart J. 153 2007 907 917 17540190
  92. [96]Salgado-Somoza A. Teijeira-Fernandez E. Fernandez A.L. Proteomic analysis of epicardial and subcutaneous adipose tissue reveals differences in proteins involved in oxidative stress Am. J. Physiol. Heart Circ. Physiol. 299 2010 H202 H209 20435850
  93. [97]Demir B. Demir E. Aciksari G. The association between the epicardial adipose tissue thickness and oxidative stress parameters in isolated metabolic syndrome patients: a multimarker approach Int. J. Endocrinol. 2014 2014 954045 PMC4233660 25530760
  94. [98]Bays H.E. Adiposopathy is "sick fat" a cardiovascular disease? J. Am. Coll. Cardiol. 57 2011 2461 2473 21679848
  95. [99]Shen W. Wang Z. Punyanita M. Adipose tissue quantification by imaging methods: a proposed classification Obes. Res. 11 2003 5 16 12529479 PMC1894646
  96. [102]Ritchie S.A. Connell J.M. The link between abdominal obesity, metabolic syndrome and cardiovascular disease Nutr. Metabol. Cardiovasc. Dis. 17 2007 319 326 17110092
  97. [103]Furukawa S. Fujita T. Shimabukuro M. Increased oxidative stress in obesity and its impact on metabolic syndrome J. Clin. Invest. 114 2004 1752 1761 15599400 PMC535065
  98. [104]Soares A.F. Guichardant M. Cozzone D. Effects of oxidative stress on adiponectin secretion and lactate production in 3T3-L1 adipocytes Free Radic. Biol. Med. 38 2005 882 889 15749384
  99. [105]Murdolo G. Piroddi M. Luchetti F. Oxidative stress and lipid peroxidation by-products at the crossroad between adipose organ dysregulation and obesity-linked insulin resistance Biochimie 95 2013 585 594 23274128
  100. [106]Singh S.P. Niemczyk M. Saini D. Role of the electrophilic lipid peroxidation product 4-hydroxynonenal in the development and maintenance of obesity in mice Biochemistry 47 2008 3900 3911 18311940
  101. [107]Grimsrud P.A. Picklo M.J. Sr Griffin T.J. Carbonylation of adipose proteins in obesity and insulin resistance: identification of adipocyte fatty acid-binding protein as a cellular target of 4-hydroxynonenal Mol. Cell. Proteomics 6 2007 624 637 17205980
  102. [108]Bost F. Aouadi M. Caron L. The role of MAPKs in adipocyte differentiation and obesity Biochimie 87 2005 51 56 15733737
  103. [109]Elrayess M.A. Almuraikhy S. Kafienah W. 4-hydroxynonenal causes impairment of human subcutaneous adipogenesis and induction of adipocyte insulin resistance Free Radic. Biol. Med. 104 2017 129 137 28088621
  104. [110]Echtay K.S. Esteves T.C. Pakay J.L. A signalling role for 4-hydroxy-2-nonenal in regulation of mitochondrial uncoupling EMBO J. 22 2003 4103 4110 12912909 PMC175801
  105. [111]Csala M. Kardon T. Legeza B. On the role of 4-hydroxynonenal in health and disease Biochim. Biophys. Acta 1852 2015 826 838 25643868
  106. [112]Negre-Salvayre A. Coatrieux C. Ingueneau C. Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors Br. J. Pharmacol. 153 2008 6 20 17643134 PMC2199390
  107. [113]Awasthi Y.C. Sharma R. Sharma A. Self-regulatory role of 4-hydroxynonenal in signaling for stress-induced programmed cell death Free Radic. Biol. Med. 45 2008 111 118 18456001 PMC2664084
  108. [114]Spickett C.M. Pitt A.R. Oxidative lipidomics coming of age: advances in analysis of oxidized phospholipids in physiology and pathology Antioxidants Redox Signal. 22 2015 1646 1666 PMC4486145 25694038
  109. [115]Serbulea V. DeWeese D. Leitinger N. The effect of oxidized phospholipids on phenotypic polarization and function of macrophages Free Radic. Biol. Med. 111 2017 156 168 28232205 PMC5511074
  110. [116]Gros L. Ishchenko A.A. Saparbaev M. Enzymology of repair of etheno-adducts Mutat. Res. 531 2003 219 229 14637257
  111. [117]Lee S.H. Blair I.A. Oxidative DNA damage and cardiovascular disease Trends Cardiovasc. Med. 11 2001 148 155 11686005
  112. [118]Nair J. De Flora S. Izzotti A. Lipid peroxidation-derived etheno-DNA adducts in human atherosclerotic lesions Mutat. Res. 621 2007 95 105 17412369
  113. [119]Schaur R.J. Siems W. Bresgen N. 4-Hydroxy-nonenal-A bioactive lipid peroxidation product Biomolecules 5 2015 2247 2337 26437435 PMC4693237
  114. [120]Navab M. Reddy S.T. Van Lenten B.J. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms Nat. Rev. Cardiol. 8 2011 222 232 21304474
  115. [121]Rossi A. Kapahi P. Natoli G. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase Nature 403 2000 103 108 10638762
  116. [122]Straus D.S. Pascual G. Li M. 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway Proc. Natl. Acad. Sci. U. S. A. 97 2000 4844 4849 10781090 PMC18320
  117. [123]Cernuda-Morollon E. Pineda-Molina E. Canada F.J. 15-Deoxy-Delta 12,14-prostaglandin J2 inhibition of NF-kappaB-DNA binding through covalent modification of the p50 subunit J. Biol. Chem. 276 2001 35530 35536 11466314
  118. [124]Shiraki T. Kamiya N. Jingami H. [Activation mechanism of PPARgamma by its endogenous ligands] Tanpakushitsu Kakusan Koso 50 2005 1660 1665 16277244
  119. [125]Lopez-Jimenez F. Cortes-Bergoderi M. Update: systemic diseases and the cardiovascular system (i): obesity and the heart Rev. Esp. Cardiol. 64 2011 140 149 21277668
  120. [126]Pennathur S. Heinecke J.W. Mechanisms for oxidative stress in diabetic cardiovascular disease Antioxidants Redox Signal. 9 2007 955 969 17508917
  121. [127]Mattson M.P. Roles of the lipid peroxidation product 4-hydroxynonenal in obesity, the metabolic syndrome, and associated vascular and neurodegenerative disorders Exp. Gerontol. 44 2009 625 633 19622391 PMC2753676
  122. [128]Vincent H.K. Powers S.K. Dirks A.J. Mechanism for obesity-induced increase in myocardial lipid peroxidation Int. J. Obes. Relat. Metab. Disord. 25 2001 378 388 11319636
  123. [129]Zhang X. Wang Z. Li J. Increased 4-hydroxynonenal formation contributes to obesity-related lipolytic activation in adipocytes PLoS One 8 2013 e70663 PMC3734238 23940618
  124. [130]Kennedy A.L. Lyons T.J. Glycation, oxidation, and lipoxidation in the development of diabetic complications Metabolism 46 1997 14 21 9439553
  125. [131]Brownlee M. Vlassara H. Cerami A. Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein Diabetes 34 1985 938 941 4029512
  126. [132]Mezzetti A. Cipollone F. Cuccurullo F. Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm Cardiovasc. Res. 47 2000 475 488 10963721
  127. [133]Bucala R. Makita Z. Vega G. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency Proc. Natl. Acad. Sci. U. S. A. 91 1994 9441 9445 7937786 PMC44828
  128. [134]Afonso C.B. Sousa B.C. Pitt A.R. A mass spectrometry approach for the identification and localization of small aldehyde modifications of proteins Arch. Biochem. Biophys. 646 2018 38 45 29580947
  129. [135]Tsikas D. Assessment of lipid peroxidation by measuring malondialdehyde (MDA) and relatives in biological samples: analytical and biological challenges Anal. Biochem. 524 2017 13 30 27789233
  130. [136]Spickett C.M. The lipid peroxidation product 4-hydroxy-2-nonenal: advances in chemistry and analysis Redox Biol. 1 2013 145 152 24024147 PMC3757682
  131. [137]Vidal N. Cavaille J.P. Graziani F. High throughput assay for evaluation of reactive carbonyl scavenging capacity Redox Biol. 2 2014 590 598 24688895 PMC3969608
  132. [138]Yan L.J. Forster M.J. Chemical probes for analysis of carbonylated proteins: a review J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 879 2011 1308 1315 PMC2995837 20732835
  133. [139]Zelzer S. Mangge H. Oberreither R. Oxidative stress: determination of 4-hydroxy-2-nonenal by gas chromatography/mass spectrometry in human and rat plasma Free Radic. Res. 49 2015 1233 1238 26053028
  134. [140]Rauli S. Puppo M.D. Magni F. Validation of malondialdehyde and 4-hydroxy-2-trans-nonenal measurement in plasma by NICI-GC-MS J. Biochem. 123 1998 918 923 9562626
  135. [141]Spies-Martin D. Sommerburg O. Langhans C.D. Measurement of 4-hydroxynonenal in small volume blood plasma samples: modification of a gas chromatographic-mass spectrometric method for clinical settings J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 774 2002 231 239 12076693
  136. [142]Golizeh M. Geib T. Sleno L. Identification of 4-hydroxynonenal protein targets in rat, mouse and human liver microsomes by two-dimensional liquid chromatography/tandem mass spectrometry Rapid Commun. Mass Spectrom. 30 2016 1488 1494 27321836
  137. [143]Gioacchini A.M. Calonghi N. Boga C. Determination of 4-hydroxy-2-nonenal at cellular levels by means of electrospray mass spectrometry Rapid Commun. Mass Spectrom. 13 1999 1573 1579 10421899
  138. [144]Colzani M. Aldini G. Carini M. Mass spectrometric approaches for the identification and quantification of reactive carbonyl species protein adducts J. Proteom. 92 2013 28 50 23597925
  139. [145]Carini M. Aldini G. Facino R.M. Mass spectrometry for detection of 4-hydroxy-trans-2-nonenal (HNE) adducts with peptides and proteins Mass Spectrom. Rev. 23 2004 281 305 15133838
  140. [146]Zarkovic K. Jakovcevic A. Zarkovic N. Contribution of the HNE-immunohistochemistry to modern pathological concepts of major human diseases Free Radic. Biol. Med. 111 2017 110 126 27993730
  141. [147]Borovic S. Rabuzin F. Waeg G. Enzyme-linked immunosorbent assay for 4-hydroxynonenal-histidine conjugates Free Radic. Res. 40 2006 809 820 17015259
  142. [148]Palinski W. Yla-Herttuala S. Rosenfeld M.E. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein Arteriosclerosis 10 1990 325 335 1693068
  143. [149]Chen Q. Esterbauer H. Jurgens G. Studies on epitopes on low-density lipoprotein modified by 4-hydroxynonenal. Biochemical characterization and determination Biochem. J. 288 Pt 1 1992 249 254 1280111 PMC1132105
  144. [150]Uchida K. Itakura K. Kawakishi S. Characterization of epitopes recognized by 4-hydroxy-2-nonenal specific antibodies Arch. Biochem. Biophys. 324 1995 241 248 8554315
  145. [151]Itakura K. Oya-Ito T. Osawa T. Detection of lipofuscin-like fluorophore in oxidized human low-density lipoprotein. 4-hydroxy-2-nonenal as a potential source of fluorescent chromophore FEBS Lett. 473 2000 249 253 10812084
  146. [152]Wakita C. Honda K. Shibata T. A method for detection of 4-hydroxy-2-nonenal adducts in proteins Free Radic. Biol. Med. 51 2011 1 4 21457776
  147. [153]Liu S. Hou W. Qin H. Oxidized LDL stimulates lipid peroxidation-derived DNA and protein adducts in human vascular endothelial and smooth muscle cells J. Huazhong Univ. Sci. Technol. Med. Sci. 35 2015 200 205 25877352
  148. [154]Arcaro A. Daga M. Cetrangolo G.P. Generation of adducts of 4-Hydroxy-2-nonenal with heat shock 60 kDa protein 1 in human promyelocytic HL-60 and monocytic THP-1 cell lines Oxid. Med. Cell Longev. 2015 2015 296146 PMC4452872 26078803
  149. [155]Uchida K. Szweda L.I. Chae H.Z. Immunochemical detection of 4-hydroxynonenal protein adducts in oxidized hepatocytes Proc. Natl. Acad. Sci. U. S. A. 90 1993 8742 8746 8378358 PMC47434
  150. [156]Weber D. Milkovic L. Bennett S.J. Measurement of HNE-protein adducts in human plasma and serum by ELISA-Comparison of two primary antibodies Redox Biol. 1 2013 226 233 24024156 PMC3757688
  151. [157]Doorn J.A. Petersen D.R. Covalent modification of amino acid nucleophiles by the lipid peroxidation products 4-hydroxy-2-nonenal and 4-oxo-2-nonenal Chem. Res. Toxicol. 15 2002 1445 1450 12437335
  152. [158]Vila A. Tallman K.A. Jacobs A.T. Identification of protein targets of 4-hydroxynonenal using click chemistry for ex vivo biotinylation of azido and alkynyl derivatives Chem. Res. Toxicol. 21 2008 432 444 18232660 PMC2760080
  153. [159]Rauniyar N. Prokai L. Isotope-coded dimethyl tagging for differential quantification of posttranslational protein carbonylation by 4-hydroxy-2-nonenal, an end-product of lipid peroxidation J. Mass Spectrom. 46 2011 976 985 22012663 PMC3197809
  154. [160]Chavez J.D. Wu J. Bisson W. Site-specific proteomic analysis of lipoxidation adducts in cardiac mitochondria reveals chemical diversity of 2-alkenal adduction J. Proteom. 74 2011 2417 2429 PMC3199298 21513823
  155. [161]Wu J. Luo X. Yan L.J. Two dimensional blue native/SDS-PAGE to identify mitochondrial complex I subunits modified by 4-hydroxynonenal (HNE) Front. Physiol. 6 2015 98 25859224 PMC4374453
  156. [162]Pecorelli A. Cervellati C. Cortelazzo A. Proteomic analysis of 4-hydroxynonenal and nitrotyrosine modified proteins in RTT fibroblasts Int. J. Biochem. Cell Biol. 81 2016 236 245 27495376
  157. [164]Gomes K.M. Campos J.C. Bechara L.R. Aldehyde dehydrogenase 2 activation in heart failure restores mitochondrial function and improves ventricular function and remodelling Cardiovasc. Res. 103 2014 498 508 24817685 PMC4155470
  158. [165]Nakamura K. Kusano K. Nakamura Y. Carvedilol decreases elevated oxidative stress in human failing myocardium Circulation 105 2002 2867 2871 12070115
  159. [166]Mak S. Lehotay D.C. Yazdanpanah M. Unsaturated aldehydes including 4-OH-nonenal are elevated in patients with congestive heart failure J. Card. Fail. 6 2000 108 114 10908084
  160. [167]Giera M. Lingeman H. Niessen W.M. Recent advancements in the LC- and GC-based analysis of malondialdehyde (MDA): a brief overview Chromatographia 75 2012 433 440 22593603 PMC3336054
  161. [168]Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma Biochem. Med. 15 1976 212 216 962904
  162. [169]Knight J.A. Pieper R.K. McClellan L. Specificity of the thiobarbituric acid reaction: its use in studies of lipid peroxidation Clin. Chem. 34 1988 2433 2438 3197281
  163. [170]Cooley J.C. Lunte C.E. Detection of malondialdehyde in vivo using microdialysis sampling with CE-fluorescence Electrophoresis 32 2011 2994 2999 22034011 PMC3517075
  164. [171]Agarwal R. Chase S.D. Rapid, fluorimetric-liquid chromatographic determination of malondialdehyde in biological samples J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 775 2002 121 126 12101069
  165. [172]Del Rio D. Pellegrini N. Colombi B. Rapid fluorimetric method to detect total plasma malondialdehyde with mild derivatization conditions Clin. Chem. 49 2003 690 692 12651835
  166. [173]Sheu J.Y. Ku H.P. Tseng W.C. Determination of thiobarbituric acid adduct of malondialdehyde using on-line microdialysis coupled with high-performance liquid chromatography Anal. Sci. 19 2003 621 624 12725404
  167. [174]Cheng G.W. Wu H.L. Huang Y.L. Automated on-line microdialysis sampling coupled with high-performance liquid chromatography for simultaneous determination of malondialdehyde and ofloxacin in whole blood Talanta 79 2009 1071 1075 19615511
  168. [175]Tsikas D. Rothmann S. Schneider J.Y. Development, validation and biomedical applications of stable-isotope dilution GC-MS and GC-MS/MS techniques for circulating malondialdehyde (MDA) after pentafluorobenzyl bromide derivatization: MDA as a biomarker of oxidative stress and its relation to 15(S)-8-iso-prostaglandin F2alpha and nitric oxide (NO) J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 1019 2016 95 111 26522895
  169. [176]Pilz J. Meineke I. Gleiter C.H. Measurement of free and bound malondialdehyde in plasma by high-performance liquid chromatography as the 2,4-dinitrophenylhydrazine derivative J. Chromatogr. B Biomed. Sci. Appl. 742 2000 315 325 10901136
  170. [177]Korchazhkina O. Exley C. Andrew Spencer S. Measurement by reversed-phase high-performance liquid chromatography of malondialdehyde in normal human urine following derivatisation with 2,4-dinitrophenylhydrazine J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 794 2003 353 362 12954387
  171. [178]Zelzer S. Oberreither R. Bernecker C. Measurement of total and free malondialdehyde by gas-chromatography mass spectrometry--comparison with high-performance liquid chromatography methology Free Radic. Res. 47 2013 651 656 23745592
  172. [179]Malaei R. Ramezani A.M. Absalan G. Analysis of malondialdehyde in human plasma samples through derivatization with 2,4-dinitrophenylhydrazine by ultrasound-assisted dispersive liquid-liquid microextraction-GC-FID approach J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 1089 2018 60 69 29763745
  173. [180]Mao J. Zhang H. Luo J. New method for HPLC separation and fluorescence detection of malonaldehyde in normal human plasma J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 832 2006 103 108 16439188
  174. [181]Lord H.L. Rosenfeld J. Volovich V. Determination of malondialdehyde in human plasma by fully automated solid phase analytical derivatization J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 877 2009 1292 1298 19124277
  175. [182]Gerard-Monnier D. Erdelmeier I. Regnard K. Reactions of 1-methyl-2-phenylindole with malondialdehyde and 4-hydroxyalkenals. Analytical applications to a colorimetric assay of lipid peroxidation Chem. Res. Toxicol. 11 1998 1176 1183 9778314
  176. [183]Siddique Y.H. Ara G. Afzal M. Estimation of lipid peroxidation induced by hydrogen peroxide in cultured human lymphocytes Dose Response 10 2012 1 10 22423225 PMC3299524
  177. [184]Steghens J.P. van Kappel A.L. Denis I. Diaminonaphtalene, a new highly specific reagent for HPLC-UV measurement of total and free malondialdehyde in human plasma or serum Free Radic. Biol. Med. 31 2001 242 249 11440836
  178. [185]Giera M. Kloos D.P. Raaphorst A. Mild and selective labeling of malondialdehyde with 2-aminoacridone: assessment of urinary malondialdehyde levels Analyst 136 2011 2763 2769 21611666
  179. [186]Manini P. Andreoli R. Sforza S. Evaluation of Alternate Isotope-Coded Derivatization Assay (AIDA) in the LC-MS/MS analysis of aldehydes in exhaled breath condensate J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 878 2010 2616 2622 20207205
  180. [187]Eggink M. Charret S. Wijtmans M. Development of an on-line weak-cation exchange liquid chromatography-tandem mass spectrometric method for screening aldehyde products in biological matrices J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 877 2009 3937 3945 19880357
  181. [188]Yu L. Liu P. Wang Y.L. Profiling of aldehyde-containing compounds by stable isotope labelling-assisted mass spectrometry analysis Analyst 140 2015 5276 5286 26086784
  182. [189]Sangalli L. Chiesa L.M. Passero E. Improved procedure for the determination of malonaldehyde by gas-chromatography with electron-capture detection as 2,4,6-trichlorophenylhydrazine derivative J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 796 2003 201 207 14552832
  183. [190]Shin H.S. Determination of malondialdehyde in human blood by headspace-solid phase micro-extraction gas chromatography-mass spectrometry after derivatization with 2,2,2-trifluoroethylhydrazine J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 877 2009 3707 3711 19800854
  184. [191]Dreissigacker U. Suchy M.T. Maassen N. Human plasma concentrations of malondialdehyde (MDA) and the F2-isoprostane 15(S)-8-iso-PGF(2alpha) may be markedly compromised by hemolysis: evidence by GC-MS/MS and potential analytical and biological ramifications Clin. Biochem. 43 2010 159 167 19850019
  185. [192]Karatas F. Karatepe M. Baysar A. Determination of free malondialdehyde in human serum by high-performance liquid chromatography Anal. Biochem. 311 2002 76 79 12441155
  186. [193]Zinellu A. Sotgia S. Deiana L. Field-amplified online sample stacking capillary electrophoresis UV detection for plasma malondialdehyde measurement Electrophoresis 32 2011 1893 1897 21688277
  187. [194]Syslova K. Kacer P. Kuzma M. Rapid and easy method for monitoring oxidative stress markers in body fluids of patients with asbestos or silica-induced lung diseases J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 877 2009 2477 2486 19574111
  188. [195]Sobsey C.A. Han J. Lin K. Development and evaluation of a liquid chromatography-mass spectrometry method for rapid, accurate quantitation of malondialdehyde in human plasma J. Chromatogr. B Analyt Technol. Biomed. Life Sci. 1029–1030 2016 205 212 27437618
  189. [196]Tsikas D. Rothmann S. Schneider J.Y. Simultaneous GC-MS/MS measurement of malondialdehyde and 4-hydroxy-2-nonenal in human plasma: effects of long-term L-arginine administration Anal. Biochem. 524 2017 31 44 27530652
  190. [197]Folden D.V. Gupta A. Sharma A.C. Malondialdehyde inhibits cardiac contractile function in ventricular myocytes via a p38 mitogen-activated protein kinase-dependent mechanism Br. J. Pharmacol. 139 2003 1310 1316 12890710 PMC1573967
  191. [198]Diaz-Velez C.R. Garcia-Castineiras S. Mendoza-Ramos E. Increased malondialdehyde in peripheral blood of patients with congestive heart failure Am. Heart J. 131 1996 146 152 8554002
  192. [199]Belch J.J. Bridges A.B. Scott N. Oxygen free radicals and congestive heart failure Br. Heart J. 65 1991 245 248 2039668 PMC1024624
  193. [200]Serdar A. Yesilbursa D. Serdar Z. Relation of functional capacity with the oxidative stress and antioxidants in chronic heart failure Congest. Heart Fail. 7 2001 309 311 11828175
  194. [201]Radovanovic S. Savic-Radojevic A. Pljesa-Ercegovac M. Markers of oxidative damage and antioxidant enzyme activities as predictors of morbidity and mortality in patients with chronic heart failure J. Card. Fail. 18 2012 493 501 22633308
  195. [202]Alarcon R.A. Fluorometric determination of acrolein and related compounds with m-aminophenol Anal. Chem. 40 1968 1704 1708 5747333
  196. [203]Bohnenstengel F. Eichelbaum M. Golbs E. High-performance liquid chromatographic determination of acrolein as a marker for cyclophosphamide bioactivation in human liver microsomes J. Chromatogr. B Biomed. Sci. Appl. 692 1997 163 168 9187396
  197. [204]Togashi M. Urano Y. Kojima H. Sensitive detection of acrolein in serum using time-resolved luminescence Org. Lett. 12 2010 1704 1707 20232900
  198. [205]Togashi M. Terai T. Kojima H. Practical fluorescence detection of acrolein in human plasma via a two-step tethering approach Chem Commun (Camb). 50 2014 14946 14948 24944098
  199. [206]El-Maghrabey M.H. Kishikawa N. Ohyama K. Analytical method for lipoperoxidation relevant reactive aldehydes in human sera by high-performance liquid chromatography-fluorescence detection Anal. Biochem. 464 2014 36 42 25017470
  200. [207]Paci A. Rieutord A. Guillaume D. Quantitative high-performance liquid chromatographic determination of acrolein in plasma after derivatization with Luminarin 3 J. Chromatogr. B Biomed. Sci. Appl. 739 2000 239 246 10755368

200 of 313 shown

Cited by

Sorted by citations

Authors
Gianazza, E., Brioschi, M., Fernandez, A. M., & Banfi, C.
Affiliations
Centro Cardiologico Monzino (IT)
Corresponding author
Banfi, Cristina
ORCID
Venue
Redox Biology
Publisher
Elsevier BV
Published
2019-05
Volume
23
Pages
101119
ISSN
2213-2317 (ISSN-L)
DOI
10.1016/j.redox.2019.101119
PMC
PMC6859589
OpenAlex
W2916986262
Cited by
152
References
8
Citations by year
2026: 20 · 2025: 27 · 2024: 24 · 2023: 17 · 2022: 21 · 2021: 25 · 2020: 13 · 2019: 5
FWCI
1.55
Type
journal article
Language
en
Open access
Licence
Locations
  • Redox Biology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • H2020 Marie Skłodowska-Curie Actions (675132)
  • Ministero della Salute (2634609)
  • Horizon 2020
Topics
  • Health Sciences › Medicine › Biochemistry › Antioxidant Activity and Oxidative Stress
  • Health Sciences › Medicine › Physiology › Nitric Oxide and Endothelin Effects
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Keywords
lipid oxidation, lipid peroxidation, advanced lipoxidation end products, carbonyl species, oxidized phospholipids, protein adducts, atherosclerosis, cardiovascular disease, endothelial dysfunction, inflammation, biomarkers, therapeutic target
MeSH terms
Animals, Cardiovascular Diseases, Disease Susceptibility, Humans, Lipoproteins, Oxidation-Reduction, Lipid Peroxidation, Biomarkers, Glycation End Products, Advanced, Oxidative Stress, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review